Progress toward generating informative porcine biomedical models using induced pluripotent stem cells

Annals of the New York Academy of Sciences

Volumn 1245, Issue 1, 2011, Pages 21-23

  West, Franklin ^a   Stice, Steven ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

Induced pluripotent; Pig; Stem cells

Indexed keywords

ARTICLE; BIOMEDICINE; DISEASE MODEL; NONHUMAN; PLURIPOTENT STEM CELL; REGENERATIVE MEDICINE; SWINE;

ANIMALIA; SUIDAE; SUS;

EID: 84855243392     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06337.x     Document Type: Article

References (9)

1. Ezashi, T. et al 2009. Derivation of induced pluripotent stem cells from pig somatic cells. Proc. Natl. Acad. Sci. U.S.A. 106: 10993-10998.
2. West, F.D. et al 2010. Porcine induced pluripotent stem cells produce chimeric offspring. Stem. Cells Dev. 19: 1211-1220.
3. West, F.D. et al 2011. Chimeric Pigs produced from induced pluripotent stem cells demonstrate germline transmission and no evidence of tumor formation in young Pigs. Stem. Cells 29: 1640-1643.
4. Wu, Z. et al 2009. Generation of Pig-induced pluripotent stem cells with a drug-inducible system. J. Mol. Cell Biol. 1: 46-54.
5. Esteban, M.A. et al 2009. Generation of induced pluripotent stem cell lines from Tibetan miniature pig. J. Biol. Chem. 284: 17634-17640.
6. Rogers, C.S. et al 2008. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 321: 1837-1841.
7. Ostedgaard, L.S. et al 2011. The DeltaF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci. Transl. Med. 74: 1-24.
8. Byrne, G.W. et al 1997. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 63: 149-155.
9. Cooper, D.K. et al 1993. Identification of alpha-galactosyl and other carbohydrate epitopes that are bound by human anti-pig antibodies: relevance to discordant xenografting in man. Transpl. Immunol. 3: 198-205.